Sebastiano Buti

机构：University of Parma, University Hospitals Parma Medical Center

发表论文 8 篇 · 总被引 61 次 · h-index 3

代表论文

• Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial (2026 · Nature Medicine · 被引 36)
• Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments (2024 · Biochemical Pharmacology · 被引 11)
• Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation (2025 · Current Oncology Reports · 被引 8)
• Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy (2026 · Journal for ImmunoTherapy of Cancer · 被引 3)
• Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? (2026 · Frontiers in Immunology · 被引 1)
• A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial (2026 · The Oncologist · 被引 1)